Trends in incidence, treatment modalities and prognosis of esophageal adenocarcinoma in the US population

被引:1
作者
Yu, Zhuoyang [1 ]
Chen, Tong [1 ]
Peng, Haoyu [1 ]
Li, Anyuan [1 ]
Wei, Yutong [1 ]
Xiao, Shiyu [2 ]
机构
[1] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Gastroenterol, 32 W Sect 2,,1st Ring Rd, Chengdu, Peoples R China
关键词
Esophageal adenocarcinoma; Incidence; Clinical characteristics; Treatment modalities; Patients' prognosis; CANCER; RISK;
D O I
10.1016/j.canep.2024.102683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Esophageal adenocarcinoma (EAC) was the predominant subtype of esophageal cancer in the Western population. However, an updated and comprehensive analysis of epidemiologic, clinical, and prognostic characteristics of esophageal adenocarcinoma is lacking. Materials and methods: This was a population-based cohort study using the Surveillance Epidemiology and EndResults (SEER) Database. Patients diagnosed with EAC between 1988 and 2020 were included. Incidence trends, clinical characteristics, treatment patterns, and relative survival were systematically analyzed. Results: The overall age-standardized incidence rate of EAC significantly increased from 1.7 per 100000 persons in 1988 to 3.6 per 100000 persons in 2020. There were no significant changes in the distribution of age group, sex, and primary site of EAC over time. However, the proportion of EAC clinically staged as I or II decreased from 35.1 % to 27.9 %. Over time, palliative chemotherapy in metastatic EAC increased from 26.7 % to 41.3 %, combination therapy was still the main treatment strategy for nonmetastatic EAC. Despite the 5-year survival rate was less than 20%, 1-year survival has experienced a moderate increase from 46.7% to 53.7%. Specifically, 1-year survival rate for nonmetastatic EAC undergoing surgery only experienced a significant increase from 80.2 % in 2004-2006 to 94.7 % in 2019-2020. For metastatic EAC, obvious improvement in 1-year survival rate was observed in those treated with systematic therapy (from 26.6 % in 2004-2006 to 41.2 % in 2019-2020). In the multivariable analysis, older age, male sex, lower household income, living without a partner, advanced TNM stage, and receiving no cancer treatment were significantly associated with poor survival. Conclusion: In summary, this population-based study of EAC patients in the US showed an increase in incidence, a shift in treatment modalities for metastatic EAC, and moderately improved 1-year survival. The search for more effective surveillance and treatment strategies should be continued in the future.
引用
收藏
页数:10
相关论文
共 24 条
[1]  
Ajani Jaffer A, 2023, J Natl Compr Canc Netw, V21, P393, DOI 10.6004/jnccn.2023.0019
[2]  
[Anonymous], OVERVIEW SEER PROGRA
[3]   Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030 [J].
Arnold, Melina ;
Laversanne, Mathieu ;
Brown, Linda Morris ;
Devesa, Susan S. ;
Bray, Freddie .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (08) :1247-1255
[4]  
Bai Z., 2024, Int J. Surg.
[5]   Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Bray, Freddie ;
Laversanne, Mathieu ;
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) :229-263
[6]   Maintenance proton pump inhibition therapy and risk of oesophageal cancer [J].
Brusselaers, Nele ;
Engstrand, Lars ;
Lagergren, Jesper .
CANCER EPIDEMIOLOGY, 2018, 53 :172-177
[7]   The Epidemiology of Esophageal Adenocarcinoma [J].
Coleman, Helen G. ;
Xie, Shao-Hua ;
Lagergren, Jesper .
GASTROENTEROLOGY, 2018, 154 (02) :390-405
[8]   Advances in diagnosis and management of cancer of the esophagus [J].
Deboever, Nathaniel ;
Jones, Christopher M. ;
Yamashita, Kohei ;
Ajani, Jaffer A. ;
Hofstetter, Wayne L. .
BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
[9]   Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer A SEER Database Analysis [J].
Dubecz, Attila ;
Gall, Isabell ;
Solymosi, Norbert ;
Schweigert, Michael ;
Peters, Jeffrey H. ;
Feith, Marcus ;
Stein, Hubert J. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) :443-447
[10]   Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma [J].
Elliott, Jessie A. ;
Reynolds, John V. .
FRONTIERS IN ONCOLOGY, 2021, 11